SYSTEMATIC REVIEW article
Front. Toxicol.
Sec. In Vitro Toxicology
Volume 7 - 2025 | doi: 10.3389/ftox.2025.1496231
This article is part of the Research TopicAdvancing In Vitro Cell Culture Practices: Achieving Truly Animal-Free Experiments and Scientifically Reliable and Reproducible MethodsView all 7 articles
Towards the Standardization of Human Platelet Lysate Production and its Comparison to Fetal Bovine Serum for Human Hematopoietic Cell Culture: A Scoping Review
Provisionally accepted
- ULQA Scientific, Bangalore, India
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Human hematopoietic cell culture (HCC) refers to the ex vivo growth of normal cells of the hematological system. These cells can be used as models to understand hematopoiesis and related malignancies. HCC also holds immense potential to help develop safer vaccines and immunotherapies, as well as donor-independent blood products. In vivo, these cells grow and differentiate in highly specialized conditions but replicating these in vitro is a significant technical challenge. Although various strategies have been developed to optimize HCC expansion, implementing them can be costly. Consequently, traditional fetal bovine serum (FBS)-containing media is the first choice, despite its disadvantages. Over the past two decades, human platelet lysate (hPL) has emerged as a viable alternative. However, variations in protocols and reporting standards across laboratories have resulted in a mixed picture regarding its feasibility to replace FBS. Thus, this study aimed to review existing literature that directly compared HCC performance in hPL and FBS supplementation. PubMed, Google Scholar, and the FCS-free database were queried between 1 January to 30 July 2024. Using pre-defined inclusion and exclusion criteria, five out of 622 relevant records were included in this scoping review. Data on the hPL production method, HCC conditions and performance were extracted. We identified gaps in the consideration of key hPL production parameters and recommend addressing them to reduce the variability observed in hPL performance. Even though hPL production parameters were repeatedly overlooked, hPL outperformed FBS supplementation in terms of cell identity and functionality across the included HCC studies. Therefore, we highlight the potential of these recommendations to overcome existing technical challenges in HCC, as well as support the development of effective FBS alternatives by enhancing the reproducibility and reporting standards of future studies.
Keywords: Fetal bovine serum (FBS), Human platelet lysate (HPL), Human hematopoietic cells, fold expansion, cell culture stability, xeno-free (XF)
Received: 13 Sep 2024; Accepted: 17 Jun 2025.
Copyright: © 2025 Jonnalagadda, Goyal and Immalaraju. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Rukmini Jonnalagadda, ULQA Scientific, Bangalore, India
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.